Categories
Change Password!
Reset Password!
For relieving chronic pain, FDA has authorized a novel Proclaim Plus spinal cord stimulation system presenting FlexBurst360 treatment.
According to the notification published on 23 August 2022, the Food and Drug Administration (FDA) has cleared a novel neurostimulation system to offer tailored relief to multiple pain regions and add more therapeutic options for evolving pain conditions. This device is similar to Proclaim XR neurostimulation system and has a battery life of up to ten years.
FlexBurst360 treatment, the company's "next generation" of its patented BurstDR stimulation, covers up to 6 pain areas of limbs and trunk, with programming that may be changed according to specific therapeutic requirements of a patient. For each patient, doctors may determine the lowest effective dosage of stimulation utilizing FlexBurst360 treatment on the Proclaim Plus system, and they can modify it based on changing pain requirements.
The system offers therapeutic settings that may be accessed via a mobile device as well. Patients may connect to the manufacturer's NeuroSphere Virtual Clinic through their mobile devices. This gives them access to remote treatment setting modifications as per their requirement. Patients can also easily connect with their doctor. Patients with chronic pain have reported "tremendous relief" utilizing spinal cord stimulation.
For people with chronic pain, the Abbott BurstDR platform has changed the game because this device can imitate the natural patterns present in the brain. With this promising device, an existing platform has thus been enhanced to treat additional patients who experience pain in various body areas and have varying pain over time.
Medscape
FDA Clears New Neurostimulation System for Chronic Pain
Megan Brooks
Comments (0)